Chinese Expert Consensus on Clinical Application of Single-pill Combination of Cholesterol-lowering Agents
10.3969/j.issn.1000-3614.2024.05.002
- VernacularTitle:降胆固醇单片复方制剂临床应用中国专家共识
- Author:
Chinese College of Cardiovascular Physician,Chinese Medical Doctor Association
;
Junbo GE
- Keywords:
single-pill combination;
atherosclerotic cardiovascular disease;
blood lipid management;
cholesterol;
combination therapy
- From:
Chinese Circulation Journal
2024;39(5):433-443
- CountryChina
- Language:Chinese
-
Abstract:
Effective lipid management can significantly reduce the burden of atherosclerotic cardiovascular disease(ASCVD).However,lipid management for ASCVD prevention and treatment in China still faces the challenges of low attainment rate and poor adherence.An increasing body of evidence suggests that a single-pill combination(SPC)of statin and non-statin agents is effective for improving blood lipid control rate,improving treatment adherence,and reducing adverse cardiovascular events.To standardize the clinical application of the cholesterol-lowering single-pill combination therapy in China,the"Chinese Expert Consensus on Clinical Application of Single-pill Combination of Cholesterol-lowering Agents"was developed with the efforts of a number of domestic experts from cardiovascular,cerebrovascular,endocrinological,and pharmacological fields.The advantages in clinical application and clinical research of cholesterol-lowering SPC were elaborated in this consensus,and the clinical pathway of lipid management for ASCVD prevention and treatment was formulated.Meanwhile,suggestions on the applicable population,usage and dosage,and management of adverse events of cholesterol-lowering SPC were provided.
